中文
About Us
Corporate Overview
Management Team
Board of Directors
Our Science
Anti-viral Platform
RNA Interference
Fatty Liver Disease
Products & Pipline
Overview
HCV
HBV
ASC09
ASC06
Partnership
Investors
Financials & Filing
Presentation Materials
News
2020
2019
2018
2017
2016
2015
2014
Careers
Investors
Financials & Filing
Presentation Materials
Announcement - Inside Information - ASC09 Fixed-Dose Combination and Ritonavir Obtained Approval from Wuhan Tongji Hospital Ethics Committee to Conduct Clinical Trial on the Treatment of New Coronavirus Infections
2020-02-05
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2020
2020-02-03
Announcement - Inside Information - Progress Regarding ASC09 Fixed-dose Combination and Ritonavir in Terms of the Treatment of New Coronavirus Infections
2020-02-03
Clarification Announcement
2020-01-29
Voluntary Announcement - Approval of Clinical Trials of HBV in China for ASC22, a Subcutaneously Administered PD-L1 Antibody
2020-01-23
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2019
2020-01-02
Next Day Disclosure Returns - Others
2019-12-31
Next Day Disclosure Returns - Share Buyback
2019-12-06
Next Day Disclosure Returns - Share Buyback
2019-12-05
Next Day Disclosure Returns - Share Buyback
2019-12-04
«
3
4
5
6
»
